Business Description
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Business History
Price Overview
Last updated: Jun 27, 2026 8:58am (just now)Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): -0.66
Total Equity: $19.03M
Shares: 32,722,438
Total Debt: $61.00M
Cash: $21.69M
EBITDA: -$12.06M
Total Debt: $61.00M
Cash: $21.69M
Revenue: $99.99M
Shares: 32,722,438
Revenue: $99.99M
Revenue: $99.99M
Revenue: $99.99M
Total Equity: $19.03M
Tax Rate: 0.0%
Equity: $19.03M
Total Debt: $61.00M
Cash: $21.69M
Current Liabilities: $17.81M
Long-Term Debt: $58.88M
Total Debt: $61.00M
Total Equity: $19.03M
Shares: 32,722,438
Shares: 32,722,438
CapEx: -$332,000
Shares: 32,722,438
Stock Price: $16.47
Net Income: -$21.47M
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
Last updated: Jun 21, 2026 7:25pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $45.2M | $45.5M | $65.4M | $79.9M | $100.0M |
| Cost of Revenue | $11.7M | $13.0M | $17.3M | $20.8M | $22.8M |
| Gross Profit | $33.4M | $32.5M | $48.1M | $59.1M | $77.2M |
| Operating Expenses | $57.2M | $73.3M | $75.3M | $80.8M | $93.6M |
| Operating Income | -$23.7M | -$40.8M | -$27.2M | -$21.7M | -$16.3M |
| Net Income | -$36.1M | -$47.1M | -$33.0M | -$27.1M | -$21.5M |
| EBITDA | -$28.4M | -$36.6M | -$22.8M | -$16.6M | -$12.1M |
| EPS | $-2.17 | $-1.91 | $-1.27 | $-0.93 | $-0.66 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 21, 2026 7:25pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $19.2M | $6.6M | $18.1M | $13.4M | $21.7M |
| Total Current Assets | $132.8M | $97.7M | $92.7M | $81.3M | $94.1M |
| Total Assets | $133.6M | $114.1M | $107.7M | $94.6M | $105.6M |
| Current Liabilities | $9.3M | $11.0M | $16.2M | $15.2M | $17.8M |
| Long-Term Debt | $49.8M | $52.9M | $57.0M | $59.5M | $58.9M |
| Total Liabilities | $60.1M | $79.3M | $87.0M | $86.6M | $86.5M |
| Total Equity | $73.5M | $34.8M | $20.7M | $8.0M | $19.0M |
| Retained Earnings | -$423.8M | -$470.9M | -$503.8M | -$531.0M | -$552.4M |
Cash Flow (Annual)
Last updated: Jun 21, 2026 7:25pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$24.6M | -$36.9M | -$19.7M | -$17.9M | -$11.0M |
| Capital Expenditure | $-384,000 | $-603,000 | $-173,000 | $-306,000 | $-332,000 |
| Free Cash Flow | -$25.0M | -$37.5M | -$19.9M | -$18.3M | -$11.3M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | -$49.5M |
| Net Change in Cash | -$7.4M | -$12.6M | $11.5M | -$4.6M | $8.3M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 8:58am (just now)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$123.3M $120.2M – $126.3M
|
$153.4M $153.3M – $153.4M
|
$187.4M $182.6M – $190.8M
|
$213.4M $207.9M – $217.4M
|
| EBITDA |
-$52.0M -$53.3M – -$50.7M
|
-$64.7M -$64.7M – -$64.7M
|
-$79.0M -$80.5M – -$77.0M
|
-$90.0M -$91.7M – -$87.7M
|
| Net Income |
-$10.5M -$25.2M – $3.7M
|
-$3.7M -$35.0M – $14.2M
|
$12.8M $12.3M – $13.1M
|
$11.8M $11.4M – $12.1M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 21, 2026 7:25pm (5d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +0.7% | +43.7% | +22.1% | +25.1% |
| Gross Profit Growth | -2.8% | +48.1% | +22.8% | +30.7% |
| Operating Income Growth | -71.9% | +33.4% | +20.3% | +24.6% |
| Net Income Growth | -30.5% | +30.0% | +17.6% | +20.9% |
| EBITDA Growth | -28.9% | +37.6% | +27.4% | +27.2% |
Insider Trading (Recent)
All SEC Form 4 codes
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-24 | Morrell Martha | F-InKind | 335.00 | $16.22 | $5,434 |
| 2026-06-19 | Geiger Uri | A-Award | 789.00 | $15.63 | $12,332 |
| 2026-06-19 | Fischer Frank M | A-Award | 1,467.00 | $15.63 | $22,929 |
| 2026-06-19 | Kumar Rakhi | A-Award | 989.00 | $15.63 | $15,458 |
| 2026-06-05 | Huennekens R Scott | A-Award | 5,368.00 | $15.74 | $84,492 |
| 2026-06-05 | Huennekens R Scott | A-Award | 2,890.00 | $0.00 | $0 |
| 2026-06-05 | Fischer Frank M | A-Award | 2,890.00 | $0.00 | $0 |
| 2026-06-05 | Fischer Frank M | A-Award | 5,368.00 | $15.74 | $84,492 |
| 2026-06-05 | Geiger Uri | A-Award | 2,890.00 | $0.00 | $0 |
| 2026-06-05 | Geiger Uri | A-Award | 5,368.00 | $15.74 | $84,492 |
| 2026-06-05 | Kumar Rakhi | A-Award | 2,890.00 | $0.00 | $0 |
| 2026-06-05 | Kumar Rakhi | A-Award | 5,368.00 | $15.74 | $84,492 |
| 2026-06-05 | Ryan Renee | A-Award | 5,368.00 | $15.74 | $84,492 |
| 2026-06-05 | Ryan Renee | A-Award | 2,890.00 | $0.00 | $0 |
| 2026-06-05 | Andrade Lisa | A-Award | 5,368.00 | $15.74 | $84,492 |
| 2026-06-05 | Andrade Lisa | A-Award | 2,890.00 | $0.00 | $0 |
| 2026-06-03 | Becker Joel | F-InKind | 1,255.00 | $15.88 | $19,929 |
| 2026-05-27 | Becker Joel | F-InKind | 1,126.00 | $17.06 | $19,210 |
| 2026-05-27 | Morrell Martha | F-InKind | 358.00 | $17.06 | $6,107 |
| 2026-05-15 | Williams Patrick F. | A-Award | 16,820.00 | $0.00 | $0 |
Narrative Economics
market-narrative step).